FeMoO4 nano material as well as preparation method and application thereof

By introducing heterogeneous single atom doping into the MoO3-x matrix and simulating the XOR activity center, FeMoO4 nanomaterial was constructed, which solved the problems of low substitution rate of single atom nanomaterials and difficulty in mimicking natural enzymes, and achieved intracellular metabolism regulation and Immune activation significantly improves the therapeutic effect of diseases such as malignant tumors.

CN118908287AActive Publication Date: 2024-11-08SHANGHAI JIAOTONG UNIV
View PDF 8 Cites 0 Cited by

Patent Information

Application Number
CN202410932645.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-12
Publication Date
2024-11-08
Estimated Expiration
2044-07-12

AI Technical Summary

Technical Problem

In the prior art, the atomic substitution rate of single-atom nanomaterials is low and difficult to simulate natural enzyme activities, limiting the precise metabolic treatment of diseases such as malignant tumors.

Method used

By introducing heterogeneous monoatom doping into the MoO3-x matrix, the metal substitution rate is improved, and the Fe2+ and tetrahedral Mo4+ active center structures in XOR are simulated, and FeMoO4 nanomaterial is constructed to realize the xanthine-uric acid metabolism pathway in tumor cells Regulation and activation of the uric acid-NLRP3-IL-1β pathway in macrophages.

Benefits of technology

The high metal substitution rate and precise tumor metabolism treatment of FeMoO4 nanomaterials have been achieved, and the anti-tumor immune response is specifically stimulated, which has significantly improved the therapeutic effect on diseases such as malignant tumors.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118908287A_ABST
    Figure CN118908287A_ABST
Patent Text Reader

Abstract

The invention provides a FeMoO4 nano material and a preparation method and application thereof, and the preparation method comprises the following steps: S1, adding a molybdenum source, fatty amine and a surface stabilizer into a high-boiling-point solvent, heating and stirring for 5-60 minutes at 60-120 DEG C, then adding an iron source, and heating and stirring for 1-60 minutes at 60-120 DEG C; transferring the mixture into a polytetrafluoroethylene autoclave, carrying out solvothermal reaction at 100-280 DEG C for 6-24 hours, washing and centrifuging by using an organic polar solvent, and dispersing in an organic non-polar solvent to obtain an oil-phase FeMoO4 nano material; s2, adopting a surface modification method, dissolving the oil-phase FeMoO4 nano material and modification molecules in an organic non-polar solvent, stirring at 25 DEG C for 0-24 hours, performing rotary evaporation at 60 DEG C for 1 hour, and adding distilled water to obtain the FeMoO4 nano material. Under the solvothermal reaction condition, a large number of defect sites are generated in situ by synthesizing and corroding a MoO3-x matrix, the defect sites are monatomic anchoring sites, in the system, the anchoring sites are anchored by monatomic Fe, and the metal substitution rate of the formed monatomic Fe nano material is as high as 20.72 wt%.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of nanomedical materials, and in particular to a FeMoO4 nanomaterial and a preparation method and application thereof. Background Art

[0002] At present, studies have found that major diseases such as malignant tumors, nerves, and heart are all related to metabolic abnormalities. Taking malignant tumors as an example, the occurrence of tumors depends on the reprogramming of cell metabolism. One of the common characteristics of tumor cell metabolism is the ability to obtain essential nutrients from a nutrient-poor environment and use these nutrients to maintain viability and generate new biomass; in addition, tumor metabolic reprogramming significantly affects signaling pathways and cell-to-cell interactions, promoting the occurrence and development of tumors. However, metabolic regulators have disadvantages such as short in vivo half-life, off-target effects, and interference with normal cell metabolism.

[0003] Studies have found that xanthine oxidoreductase (XOR) can catalyze xanthine into uric acid, and low expression of XOR is associated with poor cancer prognosis; in addition, xanthine is highly expressed in tumor tissues, and its metabolite uric acid can activate a variety of immune cells. In addition, studies have also found that uric acid molecules can stimulate immune cells to secrete proinflammatory cytokines such as IL-1β by activating the uric acid-NLRP3-IL-1β pathway in macrophages, thereby increasing the activity of T cells and other cells. Although XOR plays an important role in disease metabolism and immune microenvironment remodeling, its application is limited due to the high cost of enzyme preparation and purification, poor operational stability, sensitivity to the reaction environment, and difficulty in recycling and reuse.

[0004] Single-atom nanomaterials have made great achievements in catalysis and biomedicine due to their advantages such as high atomic utilization rate and strong metal-matrix interface interaction. The main methods for constructing single-atom nanomaterials include defect engineering strategy, spatial confinement strategy, and designed coordination strategy. At present, researchers use defect engineering to regulate the defect sites of metal oxides (such as MoO3, TiO2, and CeO2) and doped carbon materials, and use C defects, O defects, S defects, and metal defects in the carrier as "traps" to capture mononuclear metal precursors, and then anchor the single atoms through the coordination of metal single atoms with defect sites, thereby realizing the synthesis of single-atom nanomaterials and improving the atomic substitution rate. However, under high-temperature synthesis conditions, metal single atoms have high activation energy and the number of anchoring sites on the matrix is ​​limited. Under high metal dosage, the melting and aggregation of single atoms cannot be avoided, resulting in a low atomic substitution rate of single-atom nanomaterials (no more than 5wt%). In addition, natural enzymes that catalyze metabolism, such as XOR, are often complex in structure and contain multi-metal catalytic centers, which limits the development of nanomaterials that simulate the activity of metabolic enzymes. Summary of the invention

[0005] In view of the defects in the prior art, the purpose of the present invention is to provide a FeMoO4 nanomaterial and a preparation method and application thereof. 3-x The matrix achieves heterogeneous single-atom doping, which not only increases the metal substitution rate to 20.72wt%, but also accurately simulates the Fe of XOR 2+ and tetrahedron Mo 4+ Active center structure, to construct a FeMoO4 nanomaterial with XOR-like activity. After intravenous injection, it is enriched in tumor tissue, precisely regulates the xanthine-uric acid metabolic pathway in tumor cells, and cascade activates the uric acid-NLRP3-IL-1β pathway in macrophages, specifically stimulates anti-tumor immune response, and realizes precise metabolic treatment of tumors. This work focuses on the artificial simulation of natural metabolic enzymes and the regulation of cell interactions, providing nanotechnology and treatment strategies for precise metabolic remodeling of major and difficult diseases.

[0006] The first aspect of the present invention provides a method for preparing a FeMoO4 nanomaterial, comprising the following steps:

[0007] S1. Add a molybdenum source, a fatty amine and a surface stabilizer to a high boiling point solvent, heat and stir at 60-120° C. for 5-60 min, then add an iron source, heat and stir at 60-120° C. for 1-60 min; transfer the mixture to a polytetrafluoroethylene autoclave, perform a solvent thermal reaction at 100-280° C. for 6-24 h, wash and centrifuge with an organic polar solvent, and disperse in an organic non-polar solvent to obtain an oil phase FeMoO4 nanomaterial; the mass volume ratio of the high boiling point solvent, the molybdenum source, the fatty amine, the surface stabilizer and the iron source is 4-12 mL: 4-400 mg: 20-2000 mg: 0.5-10 mL: 4-400 mg;

[0008] S2. Using a surface modification method, the oil phase FeMoO4 nanomaterial and the modified molecule are dissolved in the organic non-polar solvent, stirred at 25°C for 0 to 24 hours, and then rotary evaporated at 60°C for 1 hour. After adding distilled water, the FeMoO4 nanomaterial is obtained.

[0009] In one embodiment, in step S1, the high boiling point solvent is one or more of octadecene, benzyl ether, ethylene glycol, N,N-dimethylformamide, and dimethyl sulfoxide.

[0010] In one embodiment, in step S1, the molybdenum source is one or more of molybdenum acetylacetonate, molybdenum acetate, sodium molybdate, carbonyl molybdenum, and molybdenum chloride.

[0011] In one embodiment, in step S1, the iron source is one or more of ferric acetylacetonate, ferrous acetylacetonate, ferrous oleate, ferrous acetate, pentacarbonyl iron, and ferrous gluconate.

[0012] In one embodiment, in step S1, the surface stabilizer is one or more of oleic acid, oleylamine, and oleyl alcohol; and the fatty amine is one or more of hexadecylamine, dodecylamine, tetradecylamine, and octadecylamine.

[0013] In one embodiment, in step S1, the organic non-polar solvent is one or more of dichloromethane, chloroform, n-hexane, cyclohexane, dioxane, o-dichlorobenzene, and toluene, and the organic polar solvent is one or more of acetone, ethanol, ethyl acetate, methanol, methyl pyrrolidone, medium-chain alcohol, acetonitrile, N,N-dimethylformamide, and dimethyl sulfoxide.

[0014] In one embodiment, in step S2, the modified molecule is one or more of phospholipid-polyethylene glycol, polyethylene glycol, pluronic, polyvinyl pyrrolidone, polyvinyl alcohol, Tween, vitamin E polyethylene glycol succinate, polylactic acid-co-glycolic acid, polydopamine, meso-dithiosuccinate, cysteine, mercaptosuccinic acid, citric acid and mercaptopropionic acid.

[0015] The second aspect of the present invention provides FeMoO4 nanomaterials prepared by the above-mentioned preparation method.

[0016] The third aspect of the present invention provides the application of the above-mentioned FeMoO4 nanomaterial in the regulation of disease metabolism and immune microenvironment.

[0017] In one embodiment, the disease metabolism regulation includes malignant tumors, neurological and cardiac metabolic abnormalities.

[0018] Compared with the prior art, the present invention has the following beneficial effects:

[0019] 1. In the preparation method of FeMoO4 nanomaterial provided by the present invention, under solvent thermal reaction conditions, MoO 3-x The matrix generates a large number of defect sites in situ, realizing the efficient adsorption and anchoring of heterogeneous metals. The defect sites are the anchoring sites of single atoms. In this system, the anchoring sites are anchored by single-atom Fe, and the metal substitution rate of the formed single-atom Fe nanomaterial is as high as 20.72wt%. In addition, the preparation method of FeMoO4 nanomaterial provided by the present invention can accurately simulate the Fe in XOR. 2+ and tetrahedron Mo 4+ The active center conformation provides a feasible solution and technical method for simulating the active centers of other natural enzymes.

[0020] 2. In the application of the FeMoO4 nanomaterial provided by the present invention, the FeMoO4 nanomaterial can specifically simulate the XOR enzyme, convert xanthine into uric acid, and then activate the uric acid-NLRP3-IL-1β pathway in immune cells to secrete pro-inflammatory cytokines such as IL-1β, thereby reshaping related abnormal pathways such as purine and uric acid, and further reshaping the immune microenvironment, thereby achieving metabolic treatment of metabolic abnormalities such as malignant tumors, nerves, and heart diseases. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] Other features, objects and advantages of the present invention will become more apparent from the detailed description of non-limiting embodiments made with reference to the following drawings:

[0022] Figure 1 This is a transmission electron microscope (TEM) image of the FeMoO4 nanomaterial in Example 1 of the present invention;

[0023] Figure 2 Elemental analysis (EDS-Mapping) diagram of FeMoO4 nanomaterial in Example 1 of the present invention;

[0024] Figure 3 This is a high angle annular dark field scanning transmission electron microscope (HAADF-STEM) image of the FeMoO4 nanomaterial in Example 1 of the present invention;

[0025] Figure 4 This is a particle size distribution diagram of the FeMoO4 nanomaterial in Example 2 of the present invention;

[0026] Figure 5 This is a particle size distribution diagram of the FeMoO4 nanomaterial in Example 3 of the present invention;

[0027] Figure 6 This is a particle size distribution diagram of the FeMoO4 nanomaterial in Example 4 of the present invention;

[0028] Figure 7 This is a particle size distribution diagram of the FeMoO4 nanomaterial in Example 5 of the present invention;

[0029] Figure 8 This is the in vitro XOR-like catalytic performance diagram of the FeMoO4 nanomaterial in Experimental Example 1 of the present invention (xanthine→uric acid);

[0030] Fig. 9 This is a graph showing the survival rate of B16 cells with different concentrations of FeMoO4 nanomaterials in Experimental Example 2 of the present invention;

[0031] Fig.10 This is a diagram showing the effect of FeMoO4 nanomaterials on macrophage polarization in Experimental Example 3 of the present invention;

[0032] Fig.11 This is a graph showing the effect of FeMoO4 nanomaterials on uric acid levels in tumor tissues in Application Example 1 of the present invention;

[0033] Fig.12 This is a graph showing the results of FeMoO4 nanomaterials inhibiting tumor growth in Application Example 2 of the present invention;

[0034] Fig.13 This is a diagram showing the effect of FeMoO4 nanomaterials on polarization of macrophages in tumors in Application Example 3 of the present invention;

[0035] Fig.14 The FeMoO4 nanomaterial in Application Example 3 of the present invention has an effect on CD4 + T cell impact map;

[0036] Fig.15 The FeMoO4 nanomaterials in Application Example 3 of the present invention have an effect on CD8 + Diagram of the impact of T cells. DETAILED DESCRIPTION

[0037] The present invention is described in detail below in conjunction with specific embodiments. The following embodiments will help those skilled in the art to further understand the present invention, but are not intended to limit the present invention in any form. It should be noted that, for those of ordinary skill in the art, several changes and improvements can also be made without departing from the concept of the present invention. These all belong to the protection scope of the present invention.

[0038] The present invention first provides a preparation and application of FeMoO4 nanomaterials. The FeMoO4 nanomaterials prepared under certain conditions can specifically simulate the XOR enzyme, convert xanthine into uric acid, reshape related abnormal pathways such as purine, uric acid and uric acid, and further reshape the immune microenvironment, and can achieve metabolic treatment of metabolic abnormalities such as malignant tumors, nerves, and heart diseases.

[0039] Next, the preparation method of the above-mentioned FeMoO4 nanomaterial is described:

[0040] First, a molybdenum source, a fatty amine and a surface stabilizer are added to a high boiling point solvent, heated and stirred at 60-120° C. for 5-60 minutes, and then an iron source is added, heated and stirred at 60-120° C. for 1-60 minutes; the mixture is transferred to a polytetrafluoroethylene autoclave, and a solvent thermal reaction is carried out at 100-280° C. for 6-24 hours, and then washed and centrifuged with an organic polar solvent, and dispersed in an organic non-polar solvent to obtain an oil phase FeMoO4 nanomaterial; the mass volume ratio of the high boiling point solvent, the molybdenum source, the fatty amine, the surface stabilizer and the iron source is 4-12 mL: 4-400 mg: 20-2000 mg: 0.5-10 mL: 4-400 mg;

[0041] S2. Using a surface modification method, the oil phase FeMoO4 nanomaterial and the modified molecule are dissolved in the organic non-polar solvent, stirred at 25°C for 0 to 24 hours, and then rotary evaporated at 60°C for 1 hour. After adding distilled water, the FeMoO4 nanomaterial is obtained.

[0042] In the above preparation process, the MoO3 matrix is ​​synthesized under normal pressure heating conditions; under solvothermal reaction conditions, the defect-rich MoO3 is obtained by aliphatic amine-mediated reduction and in-situ dissolution. 3-x Matrix. MoO 3-x The Mo site of the matrix can serve as the anchoring point of single atoms, capture and anchor metal single atoms, and realize the single atom doping of heterogeneous metals. 3-x The Mo vacancies in the matrix are anchored by Fe single atoms. In addition, in the process of anchoring and doping Fe single atoms using this synthetic strategy, the conformations of Mo and Fe atoms will be rearranged, and the Fe in XOR can be accurately simulated. 2+ and tetrahedron Mo 4+ The crystal structure of the active center conformation provides a feasible solution and technical method for simulating the active centers of other natural enzymes.

[0043] In one embodiment, in step S1, the high boiling point solvent is one or more of octadecene, benzyl ether, ethylene glycol, N,N-dimethylformamide, and dimethyl sulfoxide.

[0044] In some embodiments, in step S1, the molybdenum source is one or more of molybdenum acetylacetonate, molybdenum acetate, sodium molybdate, carbonyl molybdenum, and molybdenum chloride.

[0045] In some embodiments, in step S1, the iron source is one or more of ferric acetylacetonate, ferrous acetylacetonate, ferrous oleate, ferrous acetate, pentacarbonyl iron, and ferrous gluconate.

[0046] In some embodiments, in step S1, the surface stabilizer is one or more of oleic acid, oleylamine, and oleyl alcohol; the fatty amine is one or more of hexadecylamine, dodecylamine, tetradecylamine, and octadecylamine. Oleic acid and fatty amine can slowly generate water molecules in a solvent thermal system, which is beneficial to accelerate the in-situ dissolution of the MoO3 matrix and the formation of surface defect vacancies.

[0047] In some embodiments, in step S1, the organic non-polar solvent is one or more of dichloromethane, chloroform, n-hexane, cyclohexane, dioxane, o-dichlorobenzene, and toluene, and the organic polar solvent is one or more of acetone, ethanol, ethyl acetate, methanol, methyl pyrrolidone, medium-chain alcohol, acetonitrile, N,N-dimethylformamide, and dimethyl sulfoxide.

[0048] In some embodiments, in step S2, the modified molecule is one or more of phospholipid-polyethylene glycol, polyethylene glycol, pluronic, polyvinyl pyrrolidone, polyvinyl alcohol, Tween, vitamin E polyethylene glycol succinate, polylactic acid-co-glycolic acid, polydopamine, meso-dithiosuccinate, cysteine, mercaptosuccinic acid, citric acid and mercaptopropionic acid, and the modified molecule can convert the hydrophobic surface of the FeMoO4 nanomaterial into a hydrophilic surface, so that it has good colloidal stability.

[0049] The present invention will be further explained in detail below in conjunction with embodiments:

[0050] Example 1

[0051] This example provides the synthesis and characterization of FeMoO4 nanomaterials.

[0052] First, 40 mg of molybdenum acetylacetonate, 200 mg of hexadecylamine and 2.0 mL of oleic acid were added to 8 mL of octadecene, and then heated uniformly at 80°C for 10 min; 50 mg of ferric acetylacetonate was added to the above system and stirred at 80°C for 5 min; the mixture was transferred to a polytetrafluoroethylene autoclave (15 mL) and subjected to a solvothermal reaction at 160°C for 12 h; the product was washed with ethanol and centrifuged, repeated 3 times, and dispersed in chloroform to obtain an oil-phase FeMoO4 nanomaterial.

[0053] The prepared oil phase FeMoO4 nanomaterials were characterized by TEM. Figure 1 shown.

[0054] EDS-Mapping was used to analyze the element distribution in FeMoO4 nanomaterials. The results are as follows: Figure 2 shown.

[0055] HAADF-STEM was used to confirm the dispersion state of Fe atoms in FeMoO4 nanomaterials. Figure 3 shown.

[0056] Weigh 20 mg of phospholipid-polyethylene glycol (DSPE-PEG 2000 ) and 2 mg of oil phase FeMoO4 nanomaterials were dissolved in 5 mL of chloroform. Stirred at 25°C for 4 h, rotary evaporated at 60°C for 1 h, and dispersed in distilled water to obtain aqueous phase FeMoO4 nanomaterials.

[0057] Example 2

[0058] First, 40 mg of molybdenum acetylacetonate, 1000 mg of hexadecylamine and 10.0 mL of oleic acid were added to 8 mL of octadecene, and then heated uniformly at 120°C for 5 min; 400 mg of ferric acetylacetonate was added to the above system and stirred at 120°C for 5 min; the mixture was transferred to a polytetrafluoroethylene autoclave (15 mL) and subjected to a solvothermal reaction at 160°C for 12 h; the product was washed with acetone and centrifuged, repeated 3 times, and dispersed in dichloromethane to obtain an oil-phase FeMoO4 nanomaterial.

[0059] Weigh 20 mg of phospholipid-polyethylene glycol (DSPE-PEG 2000 ) and 2 mg of oil phase FeMoO4 nanomaterials were dissolved in 5 mL of chloroform. Stirred at 25°C for 4 h, rotary evaporated at 60°C for 1 h, and dispersed in distilled water to obtain aqueous phase FeMoO4 nanomaterials.

[0060] The prepared FeMoO4 nanomaterials were subjected to hydration particle size analysis, and the results are as follows: Figure 4 shown.

[0061] Example 3

[0062] First, 40 mg of molybdenum acetylacetonate, 200 mg of hexadecylamine and 2.0 mL of oleic acid were added to 8 mL of octadecene, and then heated uniformly at 120°C for 5 min; 4 mg of ferric acetylacetonate was added to the above system and stirred at 120°C for 5 min; the mixture was transferred to a polytetrafluoroethylene autoclave (15 mL) and subjected to a solvothermal reaction at 160°C for 12 h; the product was washed with acetone and centrifuged, repeated 3 times, and dispersed in dichloromethane to obtain an oil-phase FeMoO4 nanomaterial.

[0063] Weigh 20 mg of phospholipid-polyethylene glycol (DSPE-PEG 2000 ) and 2 mg of oil phase FeMoO4 nanomaterials were dissolved in 5 mL of chloroform. Rotary evaporation was performed at 60°C for 1 h, and distilled water was added to disperse the mixture to obtain aqueous phase FeMoO4 nanomaterials.

[0064] The prepared FeMoO4 nanomaterials were subjected to hydration particle size analysis, and the results are as follows: Figure 5 shown.

[0065] Example 4

[0066] First, 400 mg of molybdenum acetylacetonate, 2000 mg of hexadecylamine and 10.0 mL of oleic acid were added to 12 mL of octadecene, and then heated uniformly at 120°C for 5 min; 40 mg of ferric acetylacetonate was added to the above system and stirred at 120°C for 5 min; the mixture was transferred to a polytetrafluoroethylene autoclave (15 mL) and subjected to a solvothermal reaction at 160°C for 12 h; the product was washed with ethanol and centrifuged, repeated 3 times, and dispersed in dichloromethane to obtain an oil-phase FeMoO4 nanomaterial.

[0067] 10 mg of Pluronic F127 and 2 mg of oil-phase FeMoO4 nanomaterials were weighed and dissolved in 2 mL of dichloromethane. Stirred at 25°C for 12 h, rotary evaporated at 60°C for 1 h, and dispersed in distilled water to obtain aqueous FeMoO4 nanomaterials.

[0068] The prepared FeMoO4 nanomaterials were subjected to hydration particle size analysis, and the results are as follows: Figure 6 shown.

[0069] Example 5

[0070] First, 4 mg of molybdenum acetylacetonate, 20 mg of hexadecylamine and 0.5 mL of oleic acid were added to 4 mL of octadecene, and then heated uniformly at 100°C for 5 min; 4 mg of ferric acetylacetonate was added to the above system and stirred at 100°C for 5 min; the mixture was transferred to a polytetrafluoroethylene autoclave (15 mL) and subjected to a solvothermal reaction at 280°C for 6 h; the product was washed with ethanol and centrifuged, repeated 3 times, and dispersed in dichloromethane to obtain an oil-phase FeMoO4 nanomaterial.

[0071] 10 mg of vitamin E polyethylene glycol succinate and 2 mg of oil phase FeMoO4 nanomaterials were weighed and dissolved in 2 mL of dichloromethane. The mixture was stirred at 25°C for 12 h, and rotary evaporated at 60°C for 1 h. Distilled water was added to disperse the mixture, and aqueous phase FeMoO4 nanomaterials were obtained.

[0072] The prepared FeMoO4 nanomaterials were subjected to hydration particle size analysis, and the results are as follows: Figure 7 shown.

[0073] Experimental Example 1

[0074] This experimental example provides the ability of the FeMoO4 nanomaterial prepared in Example 1 to catalyze the production of uric acid in vitro.

[0075] Phosphate buffered saline (PBS), undoped MoO 3-xThe nanoparticle (NPs) matrix and FeMoO4 nanomaterials were co-incubated with xanthine and reacted at 37°C for 72 hours. The uric acid content was detected using a uric acid detection kit (Wuhan Elaruite Biotechnology) to evaluate the ability of FeMoO4 nanomaterials to catalyze the production of uric acid.

[0076] Reference Figure 8 As shown, MoO 3-x Nanomaterials do not have XOR-like properties; however, FeMoO4 nanomaterials simulate the Fe 2+ and tetrahedron Mo 4+ The active center conformation can realize an XOR-like catalytic process (xanthine → uric acid).

[0077] Experimental Example 2

[0078] This experimental example provides the effect of the FeMoO4 nanomaterial prepared in Example 1 on cytotoxicity.

[0079] B16 cells (6×10 3 / well) were inoculated in a 96-well plate and cultured in a cell culture incubator at 37°C for 12 h. After incubating the cells with amino acid and glucose-containing culture medium (Dulbecco's Modified Eagle Medium, DMEM) containing different concentrations (0, 1.56, 3.13, 6.25, 12.5 μg / mL) of FeMoO4 nanomaterials for 24 h, 10 μL of 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, MTT) stock solution (5 mg / mL) was added to each well and incubated in a cell culture incubator at 37°C for 2 h. After removing the MTT culture medium, 100 μL of DMSO was used to dissolve the formazan crystal precipitate, and the absorbance of each well at 570 nm was detected by a microplate reader.

[0080] Reference Fig. 9 As shown, FeMoO4 nanomaterials have no obvious cytotoxicity.

[0081] Experimental Example 3

[0082] This experimental example provides the effects of the FeMoO4 nanomaterials prepared in Example 1 on cell interactions and macrophage polarization.

[0083] B16 cells (2×10 4 / well) were inoculated in a 6-well plate and cultured in a cell culture incubator at 37°C for 12 h. 3-xB16 cells were treated with DMEM containing nanomaterials, uric acid (50 μg / mL) or FeMoO4 nanomaterials (Mo 3.13 μg / mL) for 24 h; Raw264.7 cells (5×10 4 / well) were inoculated in a 6-well plate and cultured in a cell culture incubator at 37°C for 12 h; they were then treated with interleukin 4 (IL-4) (20 ng / mL) for 12 h, and polarized to M2 type; the supernatants of B16 cells from the above different groups were added to Raw264.7 cells, and Raw264.7 cells were collected after 24 h of incubation, and stained with CD86 and CD206 antibodies, and CD86 was analyzed by flow cytometry. + Macrophages (M1 type) and CD206 + Macrophage (M2 type) ratio.

[0084] Reference Fig.10 As shown in Figure 2, the polarization ratio of macrophages in the FeMoO4 nanomaterial group was significantly stronger than that in the MoO 3-x Nanomaterials group. It is speculated that FeMoO4 nanomaterials induce tumor cells to produce and release uric acid molecules, which effectively induce macrophages to polarize toward M1 type. It can be seen that FeMoO4 nanomaterials can affect cell interactions and achieve macrophage polarization regulation in the tumor microenvironment.

[0085] Application Example 1

[0086] This application example provides the application of the FeMoO4 nanomaterial prepared in Example 1 in tumor metabolic remodeling.

[0087] B16 cells (1×10 6 ) suspension and injected into the back of male C57BL / 6 mice. One week later, mice bearing B16 melanoma were intravenously injected with PBS and FeMoO4 nanomaterials (Fe 5mg / kg). Tumor tissues were fixed and sliced, and spatial metabolomics was used to analyze the regulation of uric acid metabolism in tumor tissues by FeMoO4 nanomaterials.

[0088] Reference Fig.11 As shown in the figure, the uric acid level in the tumor of the FeMoO4 nanomaterial group was significantly higher than that of the control group. The in vivo results showed that FeMoO4 nanomaterials can effectively regulate uric acid metabolism in tumor tissues with their unique XOR enzyme properties.

[0089] Application Example 2

[0090] This application example provides the application of the FeMoO4 nanomaterial prepared in Example 1 in its tumor inhibition performance in vivo.

[0091] B16 cells (1×106 ) suspension and injected into the back of male C57BL / 6 mice; one week later, mice bearing subcutaneous B16 melanoma were randomly divided into three groups (n=5) and intravenously injected with PBS, undoped MoO 3-x After adding nanomaterials and FeMoO4 nanomaterials (Fe 5 mg / kg), the tumor volume was recorded using a vernier caliper.

[0092] Reference Fig.12 As shown in Figure 2, FeMoO4 nanomaterials can significantly inhibit tumor growth, and the inhibitory effect is stronger than that of MoO 3-x Nanomaterials Group.

[0093] Application Example 3

[0094] This application example provides the application of the FeMoO4 nanomaterial prepared in Example 1 in reshaping the tumor immune microenvironment.

[0095] B16 cells (1×10 6 ) suspension and injected into the back of male C57BL / 6 mice; one week later, mice bearing subcutaneous B16 melanoma were intravenously injected with PBS and FeMoO4 nanomaterials (Fe 5 mg / kg), respectively; tumor tissues were taken separately, treated with 0.6 mg / mL collagenase IV and 0.01 mg / mL deoxyribonuclease I (Deoxyribonuclease I, DNase I), digested in culture medium at 37°C for 1 hour, filtered with a 40 μm cell filter, and then treated with 36% Percoll layering solution and lysed red solution, respectively. The single cell suspension was co-incubated with Fc blocker, and then incubated with metal-labeled antibodies, and mass spectrometry flow cytometry was used to analyze the macrophages, CD8 + T cells and CD4 + T cell changes.

[0096] Reference Figure 13-Figure 15 As shown in the figure, FeMoO4 nanomaterials can increase the number of macrophages and CD8 + T cells and CD4 + T cell level. This may be because FeMoO4 nanomaterials induce tumor cells to produce and release uric acid molecules, thereby activating the uric acid-NLRP3-IL-1β signaling pathway in macrophages, promoting macrophages to secrete inflammatory factors such as IL-1β, and polarizing them to the M1 type. Inflammatory cytokines then promote T cell activation and enhance anti-tumor immune response.

[0097] The above describes the specific embodiments of the present invention. It should be understood that the present invention is not limited to the above specific embodiments, and those skilled in the art can make various changes or modifications within the scope of the claims, which does not affect the essence of the present invention. In the absence of conflict, the embodiments of the present application and the features in the embodiments can be combined with each other arbitrarily.

Claims

1. A method for preparing FeMoO4 nanomaterial, characterized in that: The following steps are involved: S1. Add a molybdenum source, a fatty amine and a surface stabilizer to a high boiling point solvent, heat and stir at 60-120° C. for 5-60 min, then add an iron source, heat and stir at 60-120° C. for 1-60 min; transfer the mixture to a polytetrafluoroethylene autoclave, perform a solvent thermal reaction at 100-280° C. for 6-24 h, wash and centrifuge with an organic polar solvent, and disperse in an organic non-polar solvent to obtain an oil phase FeMoO4 nanomaterial; the mass volume ratio of the high boiling point solvent, the molybdenum source, the fatty amine, the surface stabilizer and the iron source is 4-12 mL: 4-400 mg: 20-2000 mg: 0.5-10 mL: 4-400 mg; S2. Using a surface modification method, the oil phase FeMoO4 nanomaterial and the modified molecule are dissolved in the organic non-polar solvent, stirred at 25°C for 0 to 24 hours, and then rotary evaporated at 60°C for 1 hour. After adding distilled water, the FeMoO4 nanomaterial is obtained.

2. The method for preparing FeMoO4 nanomaterial according to claim 1, characterized in that: In the step S1, the high boiling point solvent is one or more of octadecene, benzyl ether, ethylene glycol, N,N-dimethylformamide, and dimethyl sulfoxide.

3. The method for preparing FeMoO4 nanomaterial according to claim 1, characterized in that: In the step S1, the molybdenum source is one or more of molybdenum acetylacetonate, molybdenum acetate, sodium molybdate, carbonyl molybdenum, and molybdenum chloride.

4. The method for preparing FeMoO4 nanomaterial according to claim 1, characterized in that: In the step S1, the iron source is one or more of ferrous acetylacetonate, ferrous acetylacetonate, ferrous oleate, ferrous acetate, pentacarbonyl iron, and ferrous gluconate.

5. The method for preparing FeMoO4 nanomaterial according to claim 1, characterized in that: In the step S1, the surface stabilizer is one or more of oleic acid, oleylamine, and oleyl alcohol; the fatty amines are one or more of hexadecylamine, dodecylamine, tetradecylamine, and octadecylamine.

6. The method for preparing FeMoO4 nanomaterial according to claim 1, characterized in that: In step S1, the organic non-polar solvent is one or more of dichloromethane, chloroform, n-hexane, cyclohexane, dioxane, o-dichlorobenzene, and toluene, and the organic polar solvent is one or more of acetone, ethanol, ethyl acetate, methanol, methyl pyrrolidone, medium-chain alcohol, acetonitrile, N,N-dimethylformamide, and dimethyl sulfoxide.

7. The method for preparing FeMoO4 nanomaterial according to claim 1, characterized in that: In step S2, the modified molecule is one or more of phospholipid-polyethylene glycol, polyethylene glycol, pluronic, polyvinyl pyrrolidone, polyvinyl alcohol, Tween, vitamin E polyethylene glycol succinate, polylactic acid-co-glycolic acid, polydopamine, meso-dithiosuccinate, cysteine, mercaptosuccinic acid, citric acid and mercaptopropionic acid.

8. A FeMoO4 nanomaterial prepared by the preparation method according to any one of claims 1 to 7.

9. Use of the FeMoO4 nanomaterial as claimed in claim 8 in disease metabolism regulation and immune microenvironment regulation.

10. The use according to claim 9, characterized in that: The disease metabolism regulation includes diseases such as malignant tumors, nerves, and cardiac metabolic abnormalities.

Citation Information

Patent Citations

  • Pluronic-modified molybdenum oxide nano-sheet as well as preparation method and application thereof

    CN108451932A

  • Preparation method, product and application of molybdenum oxide nano material

    CN109650449A

  • Molybdenum oxide nanosheet plugging hollow mesoporous silicon nano material, and preparation method and application thereof

    CN110917172A

  • Method for synthesizing MoO3-X antibacterial material with dual mimic enzyme activity

    CN111017996A

  • Preparation method of pH-responsive doped molybdenum oxide nano-enzyme capable of being rapidly degraded

    CN113526554A